Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Yasir Nagarwala"'
Autor:
Colleen Briner, Wei Ping Lee, Ruey Kuen Hsieh, Kevin M. Koch, Melissa J. LaBonte, Susan G. Urba, Heinz-Josef Lenz, Dongyun Yang, Dina Sakaeva, Peter M. Wilson, Michael J. Pishvaian, Yasir Nagarwala, Tomomi Kaneko, Oleg Gladkov, Wu Zhang, Sun Young Rha
Publikováno v:
Mol Cancer Ther
LaBonte Wilson, M, Yang, D, Wilson, P, Zhang, W, Nagarwala, Y, Koch, K, Briner, C, Kaneko, T, Rha, S-Y, Gladkov, O, Urba, S, Sakaeva, D, Pishvaian, M, Hsieh, R-K, Lee, W-P & Lenz, H-J 2016, ' A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer ', Molecular Cancer Therapeutics, vol. 15, no. 9 . https://doi.org/10.1158/1535-7163.MCT-15-0908
LaBonte Wilson, M, Yang, D, Wilson, P, Zhang, W, Nagarwala, Y, Koch, K, Briner, C, Kaneko, T, Rha, S-Y, Gladkov, O, Urba, S, Sakaeva, D, Pishvaian, M, Hsieh, R-K, Lee, W-P & Lenz, H-J 2016, ' A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer ', Molecular Cancer Therapeutics, vol. 15, no. 9 . https://doi.org/10.1158/1535-7163.MCT-15-0908
An exploratory phase II biomarker-embedded trial (LPT109747; NCT00526669) designed to determine the association of lapatinib-induced fluoropyrimidine gene changes with efficacy of lapatinib plus capecitabine as first-line treatment for advanced gastr
Autor:
Shien Guo, Gary Binder, T. Facon, James D. Cavenagh, Darrell White, Andrew R. Belch, C G Pelligra, Yasir Nagarwala, Ariel Berger, Cyrille Hulin, Wai Yiu, Supratik Basu, Saad Z. Usmani, Ajay K. Nooka, Craig J. Gibson, Annette Ervin-Haynes
Publikováno v:
Journal of Medical Economics. 19:243-258
To conduct a cost-effectiveness assessment of lenalidomide plus dexamethasone (Rd) vs bortezomib plus melphalan and prednisone (VMP) as initial treatment for transplant-ineligible patients with newly-diagnosed multiple myeloma (MM), from a U.S. payer
Autor:
Rafat Abonour, Cristina Gasparetto, Jatin J. Shah, Brian G.M. Durie, James W. Hardin, Yasir Nagarwala, Robert M. Rifkin, Howard R. Terebelo, Rosanna J. Ricafort, Shankar Srinivasan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:368-376
Background Connect MM is the first and largest observational, noninterventional, prospective registry of patients newly diagnosed with multiple myeloma (NDMM) in the United States. It collects longitudinal data on patients within clinical practice in
Autor:
Steven R. Arikian, X. Henry Hu, Saad Z. Usmani, Andy Surinach, Frank A. Corvino, Yasir Nagarwala, Gary Binder, Mohamad A. Hussein, Craig J. Gibson, Dejan Milentijevic
Publikováno v:
Current Medical Research and Opinion. 31:1105-1115
Few studies have addressed the cost patterns of patients with multiple myeloma (MM) before and after first relapse. This US claims analysis evaluated, from a US health plan perspective, patterns of total direct costs of care from treatment initiation
Autor:
Lowell L. Hart, Denise A. Yardley, Janine M. Mahoney, Linda D. Bosserman, Yasir Nagarwala, Michelle DeSilvio, Maura K. Hagan, Mansoor N. Salleh, Paul Richards, David M. Waterhouse
Publikováno v:
Breast Cancer Research and Treatment
Lapatinib, an oral, reversible inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) tyrosine kinase, has proven antitumor activity in HER2-positive metastatic breast cancer (MBC). Nanoparticle albumin-boun
Autor:
Jane Jie Lu, James W. Hardin, Jayesh Mehta, Yasir Nagarwala, Laurie Kenvin, Mohit Narang, Robert M. Rifkin, Robert Knight, Howard R. Terebelo, Brian G.M. Durie, Kathleen Toomey, Shankar Srinivasan, Jatin J. Shah, Cristina Gasparetto, Rafat Abonour
Publikováno v:
Leukemialymphoma. 57(9)
Advances in treatment have extended the survival of patients with multiple myeloma (MM),[1] but this increased survival time also increases the potential for developing second primary malignancies ...
Autor:
Mansoor N. Saleh, Yasir Nagarwala, Paul Richards, David M. Waterhouse, JM Mahoney, Linda D. Bosserman, ML DeSilvio, D. A. Yardley, Lowell L. Hart, MK Hagan
Publikováno v:
Cancer Research. 71:P1-12
Background: L, a dual kinase inhibitor of epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER2), approved for the treatment of HER2+ MBC in combination with capecitabine following progression after trastuzuma
Autor:
Gail Larkins, H.R. Terebelo, Mohit Narang, R.M. Rifkin, James W. Hardin, Yasir Nagarwala, Jayesh Mehta, Shankar Srinivasan, Jatin J. Shah, K. Toomey, Cristina Gasparetto, Rafat Abonour
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e137-e138
novel agents, i.e. velcade-based (n1⁄468) or IMiD-based regimens (n1⁄418). All 258 patients received high doses of melphalan and single (n1⁄4149) or tandem (n1⁄4109) auto-HCT. Results: Overall, after induction, 67 patients (25.9%) achieved co
Autor:
X.H. Hu, Steven R. Arikian, J. Lee, Frank A. Corvino, Mohamad A. Hussein, Gary Binder, Andy Surinach, Yasir Nagarwala, Saad Z. Usmani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e257-e258
Patterns of Growth Factor Costs in Multiple Myeloma Patients Treated With Lenalidomide or Bortezomib
Autor:
J. Lee, Yasir Nagarwala, Andy Surinach, X.H. Hu, Mohamad A. Hussein, Saad Z. Usmani, Gary Binder, Steven R. Arikian, A. Nyandege, Frank A. Corvino
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e259-e260